BioCardia, Inc. (BCDA) Stock

BioCardia, Inc. is a pioneering clinical-stage company focused on advancing regenerative medicine solutions for cardiovascular and pulmonary diseases. At the forefront of its portfolio is the CardiAMP Cell Therapy System, designed to treat heart failure and chronic myocardial ischemia. This innovative therapy harnesses cellular and cell-derived approaches to potentially enhance cardiac function and improve patient outcomes. BioCardia is also exploring allogeneic cell therapies for both cardiac and pulmonary conditions, leveraging investigational bone marrow-derived mesenchymal cells in Phase I/II trials for treating ischemic systolic heart failure.

Beyond its therapeutic innovations, BioCardia offers the Helix biotherapeutic delivery system, uniquely engineered to administer treatments directly into the heart muscle using a specialized helical needle. This technology represents a significant advancement in targeted delivery within cardiac interventions. Additionally, the company provides Morph deflectable guides and sheaths, enhancing precision and safety in minimally invasive procedures.

Established in Sunnyvale, California, BioCardia, Inc. operates with a commitment to collaboration and innovation. It has forged strategic partnerships, including a collaboration agreement with CellProthera SAS aimed at developing ProtheraCytes for acute myocardial infarction treatment. With its comprehensive approach to regenerative therapies and cutting-edge delivery systems, BioCardia continues to lead the charge in transforming cardiovascular and pulmonary care.